Anti-hypertensive drugs
PreclinicalSmall molecule
Anti-hypertensive drugs is one of 48 small molecule programs targeting Hypertension. It is currently in Preclinical.
2
Indications
3
Total Trials
1
Active Trials
47
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
160 competitors in Hypertension
#DrugCompanyPhaseTrials
1Foundayo
Eli LillyPhase 3
Nitrostat
VViatris Specialty LLC
Phase 3
Baxfendy
AstraZenecaPhase 3
Alka-Seltzer
AAbbott
Phase 3
SGLT2
PProf. Dr. med. Ingo Eitel
Phase 3
Avastin
RochePreclinical
Winrevair
Merck & Co.Preclinical
Alphagan
AbbViePreclinical
Deltavit
HHyundai Pharmaceutical Co., LTD.
Preclinical
Nipride
EExela Pharma Sciences, LLC.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Postmenopausal Women1 trial
Effect of DASH Diet and Progressive Muscle Relaxation on Cardiovascular Risks in Postmenopausal Women
Recruiting·—·N/A·NCT06600347·90 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Anti-hypertensive drugs. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of Pavia